{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:52:02Z","timestamp":1787701922540,"version":"build-2784847793"},"reference-count":50,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:p>\n                    <jats:italic>Context<\/jats:italic>\n                    .\u2014Malignant mesothelioma, of either peritoneum or pleura, is an uncommon cancer. The diagnosis is often difficult to make, in part because of the overlapping morphology of reactive and malignant mesothelial cells. Glucose transporter 1 (GLUT-1) is a glucose transporter typically found on erythrocytes, which is aberrantly expressed in various carcinomas. It has recently been reported as specific and sensitive in discriminating malignant pleural mesothelioma from reactive hyperplasia. The application of GLUT-1 staining in peritoneal mesothelioma has not been fully explored.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Objective<\/jats:italic>\n                    .\u2014To determine if GLUT-1 staining is helpful in distinguishing abdominal mesotheliomas from benign, reactive mesothelial lesions and to further study its utility in the thorax.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Design<\/jats:italic>\n                    .\u2014Tissue microarrays containing 135 abdominal malignant mesotheliomas and 30 malignant pleural mesotheliomas were stained with an antibody to GLUT-1, as were 56 reactive mesothelial lesions.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results<\/jats:italic>\n                    .\u2014The overall sensitivity and specificity for GLUT-1 in mesothelioma was 53% and 98%, respectively. The sensitivity in epithelioid malignant mesothelioma was 49% and in sarcomatoid\/biphasic malignant mesothelioma, 66%. In the thorax, the sensitivity was 50% and in the abdomen it was 54%. The positive predictive value of GLUT-1 immunoreactivity was 98% and the negative predictive value was 40%.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion<\/jats:italic>\n                    .\u2014Glucose transporter 1 staining of thoracic mesotheliomas showed high specificity but lower sensitivity than previously reported. Abdominal malignant mesotheliomas showed similar results. Because of low sensitivity, only positive staining is informative. In both sites, the utility of the stain was limited by nonspecific staining (eg, in necrotic areas) as well as bright labeling of erythrocytes and occasional lymphoid elements. Despite these limitations, GLUT-1 can help differentiate malignant mesothelioma from reactive benign mesothelium.\n                  <\/jats:p>","DOI":"10.5858\/arpa.2011-0219-oa","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T15:53:59Z","timestamp":1340898839000},"page":"804-809","source":"Crossref","is-referenced-by-count":27,"title":["Utility of Glucose Transporter 1 in the Distinction of Benign and Malignant Thoracic and Abdominal Mesothelial Lesions"],"prefix":"10.5858","volume":"136","author":[{"given":"Stephen M.","family":"Lagana","sequence":"first","affiliation":[{"name":"From the Departments of Pathology and Cell Biology (Drs Lagana and Borczuk) and Medicine-Oncology (Dr Taub), Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"Taub","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology and Cell Biology (Drs Lagana and Borczuk) and Medicine-Oncology (Dr Taub), Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain C.","family":"Borczuk","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology and Cell Biology (Drs Lagana and Borczuk) and Medicine-Oncology (Dr Taub), Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","reference":[{"issue":"5","key":"arpa-136-07-804-809-b01","series-title":"Occup Environ Med","first-page":"438","article-title":"Changing trends in US mesothelioma incidence","volume":"61","author":"Weill\n              H,","year":"2004","unstructured":"Weill\n              H, \n            \n              Hughes\n              JM, \n            \n              Churg\n              AM\n            \n          . Changing trends in US mesothelioma incidence. Occup Environ Med. 2004;61(5):438\u2013441."},{"issue":"3","key":"arpa-136-07-804-809-b02","series-title":"Arch Pathol Lab Med","first-page":"397","article-title":"Application of immunohistochemistry to the diagnosis of malignant mesothelioma","volume":"132","author":"Marchevsky\n              AM","year":"2008","unstructured":"Marchevsky\n              AM\n            \n          . Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008;132(3):397\u2013401."},{"issue":"8","key":"arpa-136-07-804-809-b03","series-title":"Arch Pathol Lab Med","first-page":"1317","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group","volume":"133","author":"Husain\n              AN,","year":"2009","unstructured":"Husain\n              AN, \n            \n              Colby\n              TV, \n            \n              Ordonez\n              NG\n            , et al. \n          Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009;133(8):1317\u20131331."},{"issue":"3","key":"arpa-136-07-804-809-b04","series-title":"Histopathology","first-page":"231","article-title":"The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2","volume":"43","author":"Attanoos\n              RL,","year":"2003","unstructured":"Attanoos\n              RL, \n            \n              Griffin\n              A, \n            \n              Gibbs\n              AR\n            \n          . The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43(3):231\u2013238."},{"issue":"6","key":"arpa-136-07-804-809-b05","series-title":"Histopathology","first-page":"561","article-title":"Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports","volume":"49","author":"King\n              J,","year":"2006","unstructured":"King\n              J, \n            \n              Thatcher\n              N, \n            \n              Pickering\n              C, \n            \n              Hasleton\n              P\n            \n          . Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology. 2006;49(6):561\u2013568."},{"issue":"2","key":"arpa-136-07-804-809-b06","series-title":"Mod Pathol","first-page":"215","article-title":"Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma","volume":"20","author":"Kato\n              Y,","year":"2007","unstructured":"Kato\n              Y, \n            \n              Tsuta\n              K, \n            \n              Seki\n              K\n            , et al. \n          Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20(2):215\u2013220."},{"issue":"5","key":"arpa-136-07-804-809-b07","series-title":"Cancer Res","first-page":"1164","article-title":"Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers","volume":"56","author":"Younes\n              M,","year":"1996","unstructured":"Younes\n              M, \n            \n              Lechago\n              LV, \n            \n              Somoano\n              JR, \n            \n              Mosharaf\n              M, \n            \n              Lechago\n              J\n            \n          . Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res. 1996;56(5):1164\u20131167."},{"issue":"6","key":"arpa-136-07-804-809-b08","series-title":"Cancer","first-page":"1046","article-title":"Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival","volume":"80","author":"Younes\n              M,","year":"1997","unstructured":"Younes\n              M, \n            \n              Brown\n              RW, \n            \n              Stephenson\n              M, \n            \n              Gondo\n              M, \n            \n              Cagle\n              PT\n            \n          . Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997;80(6):1046\u20131051."},{"issue":"1","key":"arpa-136-07-804-809-b09","series-title":"Pathol Res Pract","first-page":"24","article-title":"Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract","volume":"206","author":"Sung\n              JY,","year":"2009","unstructured":"Sung\n              JY, \n            \n              Kim\n              GY, \n            \n              Lim\n              SJ, \n            \n              Park\n              YK, \n            \n              Kim\n              YW\n            \n          . Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract. Pathol Res Pract. 2009;206(1):24\u201329."},{"issue":"5","key":"arpa-136-07-804-809-b10","series-title":"Am J Pathol","first-page":"1949","article-title":"Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways","volume":"163","author":"Borczuk\n              AC,","year":"2003","unstructured":"Borczuk\n              AC, \n            \n              Gorenstein\n              L, \n            \n              Walter\n              KL, \n            \n              Assaad\n              AA, \n            \n              Wang\n              L, \n            \n              Powell\n              CA\n            \n          . Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol. 2003;163(5):1949\u20131960."},{"issue":"4","key":"arpa-136-07-804-809-b11","series-title":"Am J Clin Pathol","first-page":"619","article-title":"The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations","volume":"135","author":"Monaco\n              SE,","year":"2011","unstructured":"Monaco\n              SE, \n            \n              Shuai\n              Y, \n            \n              Bansal\n              M, \n            \n              Krasinskas\n              AM, \n            \n              Dacic\n              S\n            \n          . The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol. 2011;135(4):619\u2013627."},{"issue":"6","key":"arpa-136-07-804-809-b12","series-title":"Diagn Cytopathol","first-page":"395","article-title":"Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations","volume":"39","author":"Ikeda\n              K,","year":"2011","unstructured":"Ikeda\n              K, \n            \n              Tate\n              G, \n            \n              Suzuki\n              T, \n            \n              Kitamura\n              T, \n            \n              Mitsuya\n              T\n            \n          . Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations. Diagn Cytopathol. 2011;39(6):395\u2013401."},{"issue":"2","key":"arpa-136-07-804-809-b13","series-title":"Cancer Cytopathol","first-page":"90","article-title":"The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions","volume":"118","author":"Hasteh\n              F,","year":"2010","unstructured":"Hasteh\n              F, \n            \n              Lin\n              GY, \n            \n              Weidner\n              N, \n            \n              Michael\n              CW\n            \n          . The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol. 2010;118(2):90\u201396."},{"issue":"4","key":"arpa-136-07-804-809-b14","series-title":"Am J Clin Pathol","first-page":"516","article-title":"Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids","volume":"131","author":"Shen\n              J,","year":"2009","unstructured":"Shen\n              J, \n            \n              Pinkus\n              GS, \n            \n              Deshpande\n              V, \n            \n              Cibas\n              ES\n            \n          . Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol. 2009;131(4):516\u2013523."},{"issue":"3","key":"arpa-136-07-804-809-b15","series-title":"Diagn Cytopathol","first-page":"156","article-title":"The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study","volume":"32","author":"Saad\n              RS,","year":"2005","unstructured":"Saad\n              RS, \n            \n              Cho\n              P, \n            \n              Liu\n              YL, \n            \n              Silverman\n              JF\n            \n          . The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol. 2005;32(3):156\u2013159."},{"issue":"2","key":"arpa-136-07-804-809-b16","series-title":"J Pathol","first-page":"251","article-title":"The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis","volume":"189","author":"Cury\n              PM,","year":"1999","unstructured":"Cury\n              PM, \n            \n              Butcher\n              DN, \n            \n              Corrin\n              B, \n            \n              Nicholson\n              AG\n            \n          . The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol. 1999;189(2):251\u2013257."},{"issue":"2","key":"arpa-136-07-804-809-b17","series-title":"Am J Clin Pathol","first-page":"253","article-title":"Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: a study of thirteen antibodies","volume":"116","author":"Roberts\n              F,","year":"2001","unstructured":"Roberts\n              F, \n            \n              Harper\n              CM, \n            \n              Downie\n              I, \n            \n              Burnett\n              RA\n            \n          . Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: a study of thirteen antibodies. Am J Clin Pathol. 2001;116(2):253\u2013262."},{"issue":"5","key":"arpa-136-07-804-809-b18","series-title":"Human pathology","first-page":"443","article-title":"p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens","volume":"25","author":"Cagle\n              PT,","year":"1994","unstructured":"Cagle\n              PT, \n            \n              Brown\n              RW, \n            \n              Lebovitz\n              RM\n            \n          . p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Human pathology. 1994;25(5):443\u2013448."},{"issue":"7","key":"arpa-136-07-804-809-b19","series-title":"Histopathology","first-page":"969","article-title":"Myogenic antigen expression is useful for differentiation between epithelioid mesothelioma and non-neoplastic mesothelial cells","volume":"56","author":"Tsukiji\n              H,","year":"2010","unstructured":"Tsukiji\n              H, \n            \n              Takeshima\n              Y, \n            \n              Amatya\n              VJ, \n            \n              Kushitani\n              K, \n            \n              Inai\n              K\n            \n          . Myogenic antigen expression is useful for differentiation between epithelioid mesothelioma and non-neoplastic mesothelial cells. Histopathology. 2010;56(7):969\u2013974."},{"issue":"11","key":"arpa-136-07-804-809-b20","series-title":"Mod Pathol","first-page":"1458","article-title":"Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium","volume":"23","author":"Sato\n              A,","year":"2010","unstructured":"Sato\n              A, \n            \n              Torii\n              I, \n            \n              Okamura\n              Y\n            , et al. \n          Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol. 2010;23(11):1458\u20131466."},{"issue":"6","key":"arpa-136-07-804-809-b21","series-title":"Am J Surg Pathol","first-page":"878","article-title":"Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation","volume":"35","author":"Shi\n              M,","year":"2011","unstructured":"Shi\n              M, \n            \n              Fraire\n              AE, \n            \n              Chu\n              P\n            , et al. \n          Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol. 2011;35(6):878\u2013882."},{"issue":"9","key":"arpa-136-07-804-809-b22","series-title":"Clin Cancer Res","first-page":"3303","article-title":"P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma","volume":"11","author":"Borczuk\n              AC,","year":"2005","unstructured":"Borczuk\n              AC, \n            \n              Taub\n              RN, \n            \n              Hesdorffer\n              M\n            , et al. \n          P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res. 2005;11(9):3303\u20133308."},{"issue":"6","key":"arpa-136-07-804-809-b23","series-title":"Mod Pathol","first-page":"742","article-title":"Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas","volume":"21","author":"Chiosea\n              S,","year":"2008","unstructured":"Chiosea\n              S, \n            \n              Krasinskas\n              A, \n            \n              Cagle\n              PT, \n            \n              Mitchell\n              KA, \n            \n              Zander\n              DS, \n            \n              Dacic\n              S\n            \n          . Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 2008;21(6):742\u2013747."},{"issue":"4","key":"arpa-136-07-804-809-b24","series-title":"Mod Pathol","first-page":"531","article-title":"CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival","volume":"23","author":"Krasinskas\n              AM,","year":"2010","unstructured":"Krasinskas\n              AM, \n            \n              Bartlett\n              DL, \n            \n              Cieply\n              K, \n            \n              Dacic\n              S\n            \n          . CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod Pathol. 2010;23(4):531\u2013538."},{"issue":"1","key":"arpa-136-07-804-809-b25","series-title":"Cancer","first-page":"51","article-title":"The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions","volume":"99","author":"Illei\n              PB,","year":"2003","unstructured":"Illei\n              PB, \n            \n              Ladanyi\n              M, \n            \n              Rusch\n              VW, \n            \n              Zakowski\n              MF\n            \n          . The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer. 2003;99(1):51\u201356."},{"issue":"5","key":"arpa-136-07-804-809-b01","series-title":"Occup Environ Med","first-page":"438","article-title":"Changing trends in US mesothelioma incidence","volume":"61","author":"Weill\n              H,","year":"2004","unstructured":"Weill\n              H, \n            \n              Hughes\n              JM, \n            \n              Churg\n              AM\n            \n          . Changing trends in US mesothelioma incidence. Occup Environ Med. 2004;61(5):438\u2013441."},{"issue":"3","key":"arpa-136-07-804-809-b02","series-title":"Arch Pathol Lab Med","first-page":"397","article-title":"Application of immunohistochemistry to the diagnosis of malignant mesothelioma","volume":"132","author":"Marchevsky\n              AM","year":"2008","unstructured":"Marchevsky\n              AM\n            \n          . Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008;132(3):397\u2013401."},{"issue":"8","key":"arpa-136-07-804-809-b03","series-title":"Arch Pathol Lab Med","first-page":"1317","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group","volume":"133","author":"Husain\n              AN,","year":"2009","unstructured":"Husain\n              AN, \n            \n              Colby\n              TV, \n            \n              Ordonez\n              NG\n            , et al. \n          Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009;133(8):1317\u20131331."},{"issue":"3","key":"arpa-136-07-804-809-b04","series-title":"Histopathology","first-page":"231","article-title":"The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2","volume":"43","author":"Attanoos\n              RL,","year":"2003","unstructured":"Attanoos\n              RL, \n            \n              Griffin\n              A, \n            \n              Gibbs\n              AR\n            \n          . The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43(3):231\u2013238."},{"issue":"6","key":"arpa-136-07-804-809-b05","series-title":"Histopathology","first-page":"561","article-title":"Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports","volume":"49","author":"King\n              J,","year":"2006","unstructured":"King\n              J, \n            \n              Thatcher\n              N, \n            \n              Pickering\n              C, \n            \n              Hasleton\n              P\n            \n          . Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology. 2006;49(6):561\u2013568."},{"issue":"2","key":"arpa-136-07-804-809-b06","series-title":"Mod Pathol","first-page":"215","article-title":"Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma","volume":"20","author":"Kato\n              Y,","year":"2007","unstructured":"Kato\n              Y, \n            \n              Tsuta\n              K, \n            \n              Seki\n              K\n            , et al. \n          Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20(2):215\u2013220."},{"issue":"5","key":"arpa-136-07-804-809-b07","series-title":"Cancer Res","first-page":"1164","article-title":"Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers","volume":"56","author":"Younes\n              M,","year":"1996","unstructured":"Younes\n              M, \n            \n              Lechago\n              LV, \n            \n              Somoano\n              JR, \n            \n              Mosharaf\n              M, \n            \n              Lechago\n              J\n            \n          . Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res. 1996;56(5):1164\u20131167."},{"issue":"6","key":"arpa-136-07-804-809-b08","series-title":"Cancer","first-page":"1046","article-title":"Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival","volume":"80","author":"Younes\n              M,","year":"1997","unstructured":"Younes\n              M, \n            \n              Brown\n              RW, \n            \n              Stephenson\n              M, \n            \n              Gondo\n              M, \n            \n              Cagle\n              PT\n            \n          . Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997;80(6):1046\u20131051."},{"issue":"1","key":"arpa-136-07-804-809-b09","series-title":"Pathol Res Pract","first-page":"24","article-title":"Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract","volume":"206","author":"Sung\n              JY,","year":"2009","unstructured":"Sung\n              JY, \n            \n              Kim\n              GY, \n            \n              Lim\n              SJ, \n            \n              Park\n              YK, \n            \n              Kim\n              YW\n            \n          . Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract. Pathol Res Pract. 2009;206(1):24\u201329."},{"issue":"5","key":"arpa-136-07-804-809-b10","series-title":"Am J Pathol","first-page":"1949","article-title":"Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways","volume":"163","author":"Borczuk\n              AC,","year":"2003","unstructured":"Borczuk\n              AC, \n            \n              Gorenstein\n              L, \n            \n              Walter\n              KL, \n            \n              Assaad\n              AA, \n            \n              Wang\n              L, \n            \n              Powell\n              CA\n            \n          . Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol. 2003;163(5):1949\u20131960."},{"issue":"4","key":"arpa-136-07-804-809-b11","series-title":"Am J Clin Pathol","first-page":"619","article-title":"The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations","volume":"135","author":"Monaco\n              SE,","year":"2011","unstructured":"Monaco\n              SE, \n            \n              Shuai\n              Y, \n            \n              Bansal\n              M, \n            \n              Krasinskas\n              AM, \n            \n              Dacic\n              S\n            \n          . The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol. 2011;135(4):619\u2013627."},{"issue":"6","key":"arpa-136-07-804-809-b12","series-title":"Diagn Cytopathol","first-page":"395","article-title":"Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations","volume":"39","author":"Ikeda\n              K,","year":"2011","unstructured":"Ikeda\n              K, \n            \n              Tate\n              G, \n            \n              Suzuki\n              T, \n            \n              Kitamura\n              T, \n            \n              Mitsuya\n              T\n            \n          . Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations. Diagn Cytopathol. 2011;39(6):395\u2013401."},{"issue":"2","key":"arpa-136-07-804-809-b13","series-title":"Cancer Cytopathol","first-page":"90","article-title":"The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions","volume":"118","author":"Hasteh\n              F,","year":"2010","unstructured":"Hasteh\n              F, \n            \n              Lin\n              GY, \n            \n              Weidner\n              N, \n            \n              Michael\n              CW\n            \n          . The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol. 2010;118(2):90\u201396."},{"issue":"4","key":"arpa-136-07-804-809-b14","series-title":"Am J Clin Pathol","first-page":"516","article-title":"Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids","volume":"131","author":"Shen\n              J,","year":"2009","unstructured":"Shen\n              J, \n            \n              Pinkus\n              GS, \n            \n              Deshpande\n              V, \n            \n              Cibas\n              ES\n            \n          . Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol. 2009;131(4):516\u2013523."},{"issue":"3","key":"arpa-136-07-804-809-b15","series-title":"Diagn Cytopathol","first-page":"156","article-title":"The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study","volume":"32","author":"Saad\n              RS,","year":"2005","unstructured":"Saad\n              RS, \n            \n              Cho\n              P, \n            \n              Liu\n              YL, \n            \n              Silverman\n              JF\n            \n          . The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol. 2005;32(3):156\u2013159."},{"issue":"2","key":"arpa-136-07-804-809-b16","series-title":"J Pathol","first-page":"251","article-title":"The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis","volume":"189","author":"Cury\n              PM,","year":"1999","unstructured":"Cury\n              PM, \n            \n              Butcher\n              DN, \n            \n              Corrin\n              B, \n            \n              Nicholson\n              AG\n            \n          . The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol. 1999;189(2):251\u2013257."},{"issue":"2","key":"arpa-136-07-804-809-b17","series-title":"Am J Clin Pathol","first-page":"253","article-title":"Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: a study of thirteen antibodies","volume":"116","author":"Roberts\n              F,","year":"2001","unstructured":"Roberts\n              F, \n            \n              Harper\n              CM, \n            \n              Downie\n              I, \n            \n              Burnett\n              RA\n            \n          . Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: a study of thirteen antibodies. Am J Clin Pathol. 2001;116(2):253\u2013262."},{"issue":"5","key":"arpa-136-07-804-809-b18","series-title":"Human pathology","first-page":"443","article-title":"p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens","volume":"25","author":"Cagle\n              PT,","year":"1994","unstructured":"Cagle\n              PT, \n            \n              Brown\n              RW, \n            \n              Lebovitz\n              RM\n            \n          . p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Human pathology. 1994;25(5):443\u2013448."},{"issue":"7","key":"arpa-136-07-804-809-b19","series-title":"Histopathology","first-page":"969","article-title":"Myogenic antigen expression is useful for differentiation between epithelioid mesothelioma and non-neoplastic mesothelial cells","volume":"56","author":"Tsukiji\n              H,","year":"2010","unstructured":"Tsukiji\n              H, \n            \n              Takeshima\n              Y, \n            \n              Amatya\n              VJ, \n            \n              Kushitani\n              K, \n            \n              Inai\n              K\n            \n          . Myogenic antigen expression is useful for differentiation between epithelioid mesothelioma and non-neoplastic mesothelial cells. Histopathology. 2010;56(7):969\u2013974."},{"issue":"11","key":"arpa-136-07-804-809-b20","series-title":"Mod Pathol","first-page":"1458","article-title":"Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium","volume":"23","author":"Sato\n              A,","year":"2010","unstructured":"Sato\n              A, \n            \n              Torii\n              I, \n            \n              Okamura\n              Y\n            , et al. \n          Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol. 2010;23(11):1458\u20131466."},{"issue":"6","key":"arpa-136-07-804-809-b21","series-title":"Am J Surg Pathol","first-page":"878","article-title":"Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation","volume":"35","author":"Shi\n              M,","year":"2011","unstructured":"Shi\n              M, \n            \n              Fraire\n              AE, \n            \n              Chu\n              P\n            , et al. \n          Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol. 2011;35(6):878\u2013882."},{"issue":"9","key":"arpa-136-07-804-809-b22","series-title":"Clin Cancer Res","first-page":"3303","article-title":"P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma","volume":"11","author":"Borczuk\n              AC,","year":"2005","unstructured":"Borczuk\n              AC, \n            \n              Taub\n              RN, \n            \n              Hesdorffer\n              M\n            , et al. \n          P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res. 2005;11(9):3303\u20133308."},{"issue":"6","key":"arpa-136-07-804-809-b23","series-title":"Mod Pathol","first-page":"742","article-title":"Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas","volume":"21","author":"Chiosea\n              S,","year":"2008","unstructured":"Chiosea\n              S, \n            \n              Krasinskas\n              A, \n            \n              Cagle\n              PT, \n            \n              Mitchell\n              KA, \n            \n              Zander\n              DS, \n            \n              Dacic\n              S\n            \n          . Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 2008;21(6):742\u2013747."},{"issue":"4","key":"arpa-136-07-804-809-b24","series-title":"Mod Pathol","first-page":"531","article-title":"CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival","volume":"23","author":"Krasinskas\n              AM,","year":"2010","unstructured":"Krasinskas\n              AM, \n            \n              Bartlett\n              DL, \n            \n              Cieply\n              K, \n            \n              Dacic\n              S\n            \n          . CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod Pathol. 2010;23(4):531\u2013538."},{"issue":"1","key":"arpa-136-07-804-809-b25","series-title":"Cancer","first-page":"51","article-title":"The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions","volume":"99","author":"Illei\n              PB,","year":"2003","unstructured":"Illei\n              PB, \n            \n              Ladanyi\n              M, \n            \n              Rusch\n              VW, \n            \n              Zakowski\n              MF\n            \n          . The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer. 2003;99(1):51\u201356."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/136\/7\/article-p804.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/136\/7\/804\/1440443\/arpa_2011-0219-oa.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/136\/7\/article-p804.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/136\/7\/article-p804.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:13:26Z","timestamp":1770772406000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/136\/7\/article-p804.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":50,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.5858\/arpa.2011-0219-oa","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}